Many regulatory professionals first encountered the concept of Predetermined Change Control Plans (PCCPs) through the FDA's work on Artificial Intelligence and Machine Learning (AI/ML)-enabled medical devices, where they were proposed as a mechanism to manage adaptive algorithms and controlled software evolution without requiring repeated regulatory submissions.
However, the legal basis for PCCPs extends well beyond AI. In December 2022, the Food and Drug Omnibus Reform Act (FDORA) introduced Section 515C into the Federal Food, Drug, and Cosmetic Act, explicitly authorizing the FDA to approve Predetermined Change Control Plans for medical devices submitted through the 510(k) and PMA pathways. This statutory change transformed PCCPs from an AI-focused regulatory concept into a legislative tool applicable across the medical device sector.
The FDA's August 2024 draft guidance is therefore not creating PCCPs—it is explaining how the Agency intends to implement the authority granted under FDORA. More importantly, it makes clear that the scope is far broader than AI/ML-enabled software. PCCPs are positioned as a general regulatory mechanism for pre-authorizing defined future device modifications across a wide range of medical technologies.
Although still a draft guidance, this represents a meaningful evolution in regulatory strategy. It enables manufacturers to define, justify, and validate certain future changes upfront so that, once authorized as part of a 510(k), De Novo, or PMA submission, those changes can be implemented without additional premarket submissions, provided they remain within the approved framework.
This is more than procedural flexibility. It reflects a further implementation of the FDA's long-standing least burdensome philosophy, shifting regulatory oversight from repeated premarket submissions toward robust lifecycle planning and controlled change management.
Viewed in a global regulatory context, the PCCP framework highlights an important difference between the US and EU approaches to managing post-market changes.
Under the MDR and IVDR, manufacturers must inform their Notified Body of significant or substantial changes that may affect the certified device or quality management system. While MDCG guidance provides principles for assessing such changes, the Regulations do not define all scenarios, leaving the Notified Body to determine the regulatory consequences. Depending on the nature of the change, this may range from accepting the existing certification to requiring additional assessment, certificate amendments or, in some cases, a new conformity assessment. Because significant changes are generally evaluated individually, each change may trigger additional regulatory interactions with the Notified Body, adding time, cost, and a degree of uncertainty to lifecycle management.
The FDA's PCCP framework takes a different approach. Rather than evaluating each change individually when it is proposed, the FDA allows manufacturers to obtain prospective agreement on a defined set of future modifications and the processes used to validate and implement them. Once the PCCP is approved, oversight shifts from repeated premarket review to verification during FDA inspections or MDSAP audits that the authorized changes have been implemented in accordance with the approved PCCP and the manufacturer's quality system.
This does not reduce regulatory oversight, it relocates it. In doing so, the PCCP framework represents a further implementation of the FDA's long-standing least burdensome philosophy, providing manufacturers with greater predictability while maintaining robust regulatory control through the quality system.
While PCCPs are often discussed in regulatory strategy terms, their real impact will be felt in quality systems, inspections, and audits. Even though FDA approves the PCCP at the marketing submission stage, the real test comes later:
In practice, PCCPs shift regulatory burden:
from “pre-market submission for every change”
to “robust lifecycle control and inspection-ready execution”
This makes design controls, risk management, and configuration management more important than ever.
One of the most practically useful aspects of the guidance is the explicit list of modifications that may or may not be suitable for inclusion in a PCCP.
Importantly, several of the “allowed” categories still represent significant changes under traditional FDA interpretation—meaning PCCPs do not eliminate regulatory seriousness; they front-load it into the original authorization.
Examples from the FDA Guidance:
It is important to emphasize that this remains a draft guidance, not a final rule. However, its direction is clear. The PCCP framework signals FDA’s intent to:
For manufacturers, this is not just a compliance mechanism—it is a strategic design tool that allows regulatory planning to be embedded into product architecture from the outset.
The PCCP guidance represents a subtle but important evolution in FDA regulatory thinking. While it does not lower safety expectations, it redefines when and how those expectations are evaluated. In contrast to increasingly rigid approaches seen in the EU MDR/IVDR landscape, the US model continues to lean into structured flexibility and lifecycle efficiency.
For manufacturers, the key message is clear: Regulatory strategy is shifting upstream—from change control at execution time to change design at submission time. And while inspection and audit scrutiny will remain essential checkpoints, PCCPs offer a pathway toward more predictable, scalable, and innovation-friendly regulatory lifecycle management.
As the FDA continues to evolve its approach to lifecycle management, manufacturers need more than regulatory knowledge. They need a strategy that integrates regulatory requirements with quality systems, risk management, and product development.
Qserve supports medical device manufacturers throughout the entire product lifecycle, from regulatory strategy and submission planning to design control, quality management system implementation, software validation, and post-market compliance. Whether you are evaluating if a Predetermined Change Control Plan is appropriate for your device, preparing a 510(k), De Novo, or PMA submission, or strengthening your quality system to ensure inspection readiness, our experts can help you develop a practical and compliant approach.
Interested in understanding how PCCPs could fit into your regulatory strategy? Contact Qserve to discuss your device, your planned modifications, and the most effective pathway to market while maintaining compliance throughout the product lifecycle.